| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Silvia S Pierangeli | |
| Rohan Willis | |||
| P2860 | cites work | The role of beta2-glycoprotein I (beta2GPI) in the activation of plasminogen | Q24304748 |
| Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H) | Q24558202 | ||
| Molecular analysis of major histocompatibility complex alleles associated with the lupus anticoagulant | Q24633473 | ||
| {beta}2 Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome | Q28115185 | ||
| HLA class II alleles associations of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus | Q28138464 | ||
| Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2' | Q28179249 | ||
| Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies | Q28203584 | ||
| Antiphospholid antibodies regulate the expression of trophoblast cell adhesion molecules | Q28213303 | ||
| Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus | Q28261335 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor | Q28565242 | ||
| Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG antibodies in patients with systemic lupus erythematosus--possible association with thrombotic and thrombocytopenic complications | Q33328347 | ||
| GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. | Q33329778 | ||
| Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications | Q33337451 | ||
| Complement C3 activation is required for antiphospholipid antibody-induced fetal loss | Q33340713 | ||
| Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome | Q33341518 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| IgG anti-cardiolipin antibodies in murine lupus | Q33345088 | ||
| A family study of the antiphospholipid syndrome associated with other autoimmune diseases | Q33356141 | ||
| Antiphosphatidylserine antibodies affect rat yolk sacs in culture: a mechanism for fetal loss in antiphospholipid syndrome | Q75352534 | ||
| Annexin V is critical in the maintenance of murine placental integrity | Q77326060 | ||
| Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo | Q77342565 | ||
| Action of anticardiolipin and antibodies to beta2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death | Q77367365 | ||
| Origin of antiphospholipid antibodies: induction of aPL by viral peptides | Q77549928 | ||
| The antiphospholipid syndrome | Q77739053 | ||
| A role for the polymorphism at position 247 of the beta2-glycoprotein I gene in the generation of anti-beta2-glycoprotein I antibodies in the antiphospholipid syndrome | Q78124733 | ||
| Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides | Q78248010 | ||
| Suppressed intrinsic fibrinolytic activity by monoclonal anti-beta-2 glycoprotein I autoantibodies: possible mechanism for thrombosis in patients with antiphospholipid syndrome | Q78531445 | ||
| The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies | Q79326313 | ||
| Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V | Q79992039 | ||
| Atherogenic oxidized low-density lipoprotein/beta2-glycoprotein I (oxLDL/beta2GPI) complexes in patients with systemic lupus erythematosus and antiphospholipid syndrome | Q80084490 | ||
| Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome | Q80249563 | ||
| The placental bed in pregnancies complicated by primary antiphospholipid syndrome | Q80349512 | ||
| Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation | Q80851651 | ||
| Impaired inactivation by antithrombin and hirudin and preserved fibrinogen-clotting activity of thrombin in complex with anti-thrombin antibody from a patient with antiphospholipid syndrome | Q81094102 | ||
| Diffuse alveolar hemorrhage: a nonthrombotic antiphospholipid lung syndrome? | Q81569794 | ||
| Complement activation in patients with primary antiphospholipid syndrome | Q81638094 | ||
| Antiphospholipid antibodies limit trophoblast migration by reducing IL-6 production and STAT3 activity | Q82782633 | ||
| Anti-annexin II antibody is associated with thrombosis and/or pregnancy morbidity in antiphospholipid syndrome and systemic lupus erythematosus with thrombosis | Q83189092 | ||
| Anti-beta2-glycoprotein I antibodies are associated with pregnancy loss in women with the lupus anticoagulant | Q83290011 | ||
| Antiphospholipid antibodies and the protein C pathway | Q83954291 | ||
| Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort | Q83954302 | ||
| Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor | Q74515425 | ||
| Factor V Leiden, prothrombin gene mutation, and thrombosis risk in patients with antiphospholipid antibodies | Q74614839 | ||
| Tissue plasminogen activator and its receptor in the human amnion, chorion, and decidua at preterm and term | Q74620113 | ||
| Prothrombin mutation is not associated with thrombosis in patients with antiphospholipid syndrome | Q74823604 | ||
| Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies: a review of the literature | Q36951078 | ||
| New targeted therapies for treatment of thrombosis in antiphospholipid syndrome | Q36998932 | ||
| Antiphospholipid syndrome (APS): where does it come from? | Q37027969 | ||
| Platelets and the antiphospholipid syndrome | Q37283013 | ||
| Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome | Q37283029 | ||
| Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway | Q37409260 | ||
| MyD88 adapter-like (Mal)/TIRAP interaction with TRAF6 is critical for TLR2- and TLR4-mediated NF-kappaB proinflammatory responses. | Q37433320 | ||
| Antiphospholipid antibodies and malignancies | Q37455366 | ||
| Circulating microparticles, lupus anticoagulant and recurrent miscarriages | Q37467520 | ||
| Genetic risk factors of thrombosis in the antiphospholipid syndrome | Q37573851 | ||
| Factor XIII Val34Leu polymorphism does not contribute to the prevention of thrombotic complications in patients with antiphospholipid syndrome. | Q33359260 | ||
| The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus | Q33360375 | ||
| Infection, vaccines and other environmental triggers of autoimmunity | Q33368133 | ||
| Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson's) syndrome | Q33369424 | ||
| Anticardiolipin antibodies in NZW x BXSB F1 mice. A model of antiphospholipid syndrome | Q33369548 | ||
| Antiphospholipid antibodies: paradigm in transition | Q33382848 | ||
| Non-criteria manifestations of antiphospholipid syndrome | Q33388991 | ||
| Familial occurrence of the antiphospholipid syndrome | Q33416287 | ||
| Lupus pregnancy. A prospective study of placental changes | Q33447262 | ||
| Antiphospholipid antibodies--autoantibodies with a difference | Q33447302 | ||
| Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes | Q33448386 | ||
| (NZW x BXSB)F1 mouse. A new animal model of idiopathic thrombocytopenic purpura | Q33449588 | ||
| High incidence of anticardiolipin antibodies in relatives of patients with systemic lupus erythematosus | Q33455163 | ||
| Thrombocytopenia in SLE and related autoimmune disorders: association with anticardiolipin antibody | Q33459225 | ||
| Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant | Q33478061 | ||
| Familial association of the lupus anticoagulant | Q33486846 | ||
| A family study of anticardiolipin antibodies and associated clinical conditions | Q33487561 | ||
| V gene analysis of anti-cardiolipin antibodies from (NZW x BXSB) F1 mice. | Q33491181 | ||
| Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. | Q33491640 | ||
| Different manifestations of the antiphospholipid antibody syndrome in a family with systemic lupus erythematosus | Q33494551 | ||
| Thrombocytopenia in the antiphospholipid syndrome | Q33495555 | ||
| The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. | Q33501859 | ||
| Familial coexistence of primary antiphospholipid syndrome and factor VLeiden | Q33502615 | ||
| Multigenic control of lupus-associated antiphospholipid syndrome in a model of (NZW x BXSB) F1 mice | Q33503790 | ||
| Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome | Q33630007 | ||
| Antibodies to serine proteases in the antiphospholipid syndrome | Q33670367 | ||
| International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop | Q33685960 | ||
| Impaired fibrinolysis in the antiphospholipid syndrome | Q33822542 | ||
| Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. | Q33967600 | ||
| Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome | Q34021310 | ||
| World distribution of factor V Leiden | Q34057587 | ||
| beta2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation | Q34245642 | ||
| Association of HLA-DR5 (possibly DRB1*1201) with the primary antiphospholipid syndrome in Mexican patients. | Q34296850 | ||
| Origin of antiphospholipid antibodies. | Q34354708 | ||
| Mechanisms of antiphospholipid antibody-associated pregnancy complications | Q37576620 | ||
| Toll-like receptors in pregnancy disorders and placental dysfunction | Q37623527 | ||
| Antiphospholipid syndrome and central nervous system | Q37736754 | ||
| Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation. | Q37788783 | ||
| Antithrombin III, protein C, and protein S. Naturally occurring anticoagulant proteins | Q39484488 | ||
| TLR2 is one of the endothelial receptors for beta 2-glycoprotein I. | Q39684424 | ||
| Diffuse alveolar hemorrhage in the antiphospholipid syndrome: spectrum of disease and treatment. | Q40639385 | ||
| Placental changes in a first trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome; a case report and review of the literature | Q40980420 | ||
| The role of placental trophoblast in the pathophysiology of the antiphospholipid antibody syndrome | Q41059604 | ||
| The potential roles of endogenous retroviruses in autoimmunity | Q41225538 | ||
| Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR. | Q41287929 | ||
| Familial lupus anticoagulants | Q41466921 | ||
| Leptin modulates extracellular matrix molecules and metalloproteinases: possible implications for trophoblast invasion | Q42493849 | ||
| V gene analysis of anticardiolipin antibodies from MRL-lpr/lpr mice | Q42799873 | ||
| Statins for the treatment of antiphospholipid syndrome? | Q43275855 | ||
| Impact of plasma homocysteine and prothrombin G20210 A on primary antiphospholipid syndrome | Q43816517 | ||
| Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo | Q43882937 | ||
| Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo | Q44106531 | ||
| Valine/valine genotype at position 247 of the beta2-glycoprotein I gene in Mexican patients with primary antiphospholipid syndrome: association with anti-beta2-glycoprotein I antibodies | Q44305352 | ||
| Antiphospholipid antibodies affect human endometrial angiogenesis. | Q44526752 | ||
| Intrauterine fetal death in mice caused by cytomegalovirus-derived peptide induced aPL antibodies | Q45077755 | ||
| Antibodies to cardiolipin in normal C57BL/6J mice: induction by estrogen but not dihydrotestosterone | Q45093022 | ||
| Characterization of estrogen-induced autoantibodies to cardiolipin in non-autoimmune mice | Q45105184 | ||
| Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation | Q45111033 | ||
| Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with antiphospholipid antibodies | Q45228945 | ||
| Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients | Q45870360 | ||
| Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. | Q45971368 | ||
| Primary antiphospholipid syndrome: a low-grade auto-inflammatory disease? | Q46309832 | ||
| Platelet activation by dimeric beta2-glycoprotein I requires signaling via both glycoprotein Ibalpha and apolipoprotein E receptor 2'. | Q46591794 | ||
| Functional and binding studies of the roles of prothrombin and beta 2-glycoprotein I in the expression of lupus anticoagulant activity | Q46744324 | ||
| Cardiolipin antibodies and null alleles of C4 in black Americans with systemic lupus erythematosus | Q46797757 | ||
| HLA-DRB1 alleles and beta 2 glycoprotein I-dependent anticardiolipin antibodies in Japanese patients with systemic lupus erythematosus. | Q47677888 | ||
| Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes | Q47685798 | ||
| Thrombogenic properties of antiphospholipid antibodies do not depend on their binding to beta2 glycoprotein 1 (beta2GP1) alone | Q47719662 | ||
| Human antiphospholipid antibodies induce TNFalpha in monocytes via Toll-like receptor 8. | Q47758501 | ||
| Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes | Q48245672 | ||
| Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings | Q48371040 | ||
| Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis | Q48394757 | ||
| Familial anticardiolipin antibodies and C4 deficiency genotypes that coexist with MHC DQB1 risk factors. | Q49185648 | ||
| Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. | Q50196335 | ||
| A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. | Q50535183 | ||
| Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels. | Q50619716 | ||
| The risk for thromboembolic disease in lupus anticoagulant patients due to pathways involving P-selectin and CD154. | Q50700698 | ||
| Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies--a crucial role for acquired free protein S deficiency. | Q51000496 | ||
| Anti-phospholipid antibodies following vaccination with recombinant hepatitis B vaccine. | Q51836286 | ||
| Ontogeny of beta 2 glycoprotein I and annexin V in villous placenta of normal and antiphospholipid syndrome pregnancies. | Q52166268 | ||
| C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies. | Q53525527 | ||
| The prevalence of factor V Arg306-->Thr (factor V Cambridge) and factor V Arg306-->Gly mutations in different human populations. | Q54103720 | ||
| Anti-beta-2 glycoprotein I antibodies affect Bcl-2 and Bax trophoblast expression without evidence of apoptosis. | Q54591463 | ||
| Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome. | Q54599187 | ||
| Viral infections and antiphospholipid antibodies | Q34522953 | ||
| TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells | Q34953661 | ||
| Heterogeneity of laboratory test results for antiphospholipid antibodies in patients treated with chlorpromazine and other phenothiazines | Q35000251 | ||
| Antiphospholipid syndrome: a comprehensive review of a complex and multisystemic disease. | Q35004519 | ||
| Possible pathomechanism of autoimmune hepatitis | Q35043133 | ||
| Viral origin of antiphospholipid antibodies: endothelial cell activation and thrombus enhancement by CMV peptide-induced APL antibodies | Q35085905 | ||
| Pregnancy complications of the antiphospholipid syndrome | Q35135353 | ||
| Immune Recognition at the Maternal‐Fetal Interface: Overview | Q35176986 | ||
| Annexin A5 polymorphism (-1C-->T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome | Q35638142 | ||
| Theodore E. Woodward Award: antiphospholipid syndrome revisited: a disorder initiated by inflammation | Q35778578 | ||
| Induction of antiphospholipid autoantibodies by immunization with beta 2 glycoprotein I (apolipoprotein H). | Q35822651 | ||
| Antiprothombin antibodies and the diagnosis of antiphospholipid syndrome | Q35829186 | ||
| Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. | Q35844573 | ||
| Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome | Q35849691 | ||
| Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome | Q35874202 | ||
| Beta 2 glycoprotein I--function in health and disease | Q35928646 | ||
| Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies | Q35928725 | ||
| Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury | Q36007691 | ||
| Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies | Q36013878 | ||
| P-selectin glycoprotein ligand-1 VNTR polymorphisms and risk of thrombosis in the antiphospholipid syndrome | Q36013889 | ||
| Current trends in drug-induced autoimmunity | Q36180084 | ||
| Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. | Q36222874 | ||
| Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction | Q36228832 | ||
| Antiphospholipid antibodies as a cause of pulmonary capillaritis and diffuse alveolar hemorrhage: a case series and literature review | Q36330065 | ||
| Infectious origin of the antiphospholipid syndrome | Q36339540 | ||
| (NZW x BXSB)F1 hybrid. A model of acute lupus and coronary vascular disease with myocardial infarction | Q36345299 | ||
| Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies | Q36470411 | ||
| Kidney disease in antiphospholipid syndrome | Q36552689 | ||
| The environment and antiphospholipid syndrome | Q36677026 | ||
| Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process? | Q36785674 | ||
| The Th1/Th2 paradigm: still important in pregnancy? | Q36878453 | ||
| Antiphospholipid antibodies: effects on trophoblast and endothelial cells | Q36881604 | ||
| Activated protein C. | Q36884324 | ||
| Atherogenic antiphospholipid antibodies in antiphospholipid syndrome | Q36951070 | ||
| Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi. | Q54659449 | ||
| [Antiphospholipid antibodies, antiphospholipid syndrome and viral infections]. | Q55239351 | ||
| Familial antiphospholipid antibody syndrome: Criteria for disease and evidence for autosomal dominant inheritance | Q57186231 | ||
| Annexin A2 mediates endothelial cell activation by antiphospholipid/anti- 2 glycoprotein I antibodies | Q57374964 | ||
| Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure | Q57523494 | ||
| Major histocompatibility complex associations with primary antiphospholipid syndrome | Q58143748 | ||
| Anti–β2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor α and tissue factor by signal transduction pathways involving lipid rafts | Q59140753 | ||
| Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia | Q61415575 | ||
| Human Cytomegalovirus Induces Systemic Immune Activation Characterized by a Type 1 Cytokine Signature | Q61863439 | ||
| Double heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/IIIa increases arterial thrombosis and arteriosclerosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus | Q61914462 | ||
| Associations of anti-beta2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups | Q61943923 | ||
| Polymorphisms of the tissue factor pathway inhibitor gene are associated with venous thromboembolism in the antiphospholipid syndrome and carriers of factor V Leiden | Q63256423 | ||
| Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation | Q64128444 | ||
| Different clinical presentations of a lupus anticoagulant in the same family | Q67997333 | ||
| Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies | Q68037355 | ||
| Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant | Q68062342 | ||
| Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor | Q68090535 | ||
| The Y chromosome from autoimmune BXSB/MpJ mice induces a lupus-like syndrome in (NZW x C57BL/6)F1 male mice, but not in C57BL/6 male mice | Q68094972 | ||
| Syndrome of the black swan | Q69418368 | ||
| Acute SLE in F1 hybrids between SB/Le and NZW mice; prominently enhanced formation of gp70 immune complexes by a Y chromosome-associated factor from SB/Le mice | Q71251879 | ||
| Coexistence of familial antiphospholipid syndrome and factor V Leiden: impact on thrombotic diathesis | Q71397165 | ||
| Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant | Q71593361 | ||
| Antiphospholipid antibodies activate vascular endothelial cells | Q71747732 | ||
| An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation | Q72135926 | ||
| Connective tissue disease and the chronic biologic false-positive test for syphilis (BFP reaction) | Q72190106 | ||
| Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion | Q72361563 | ||
| Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes | Q72384713 | ||
| The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation | Q72416328 | ||
| Lupus anticoagulant: a familial observation | Q72528453 | ||
| The effect of immunoglobulin G fractions from patients with lupus anticoagulant on placental prostacyclin and thromboxane production | Q72671943 | ||
| Clinical expression of systemic lupus erythematosus in patients with C4A deficiency | Q72856599 | ||
| Inhibition of heparin/antithrombin III cofactor activity by anticardiolipin antibodies: a mechanism for thrombosis | Q72905690 | ||
| Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion | Q72995002 | ||
| Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant | Q73028016 | ||
| Correlation between beta2-glycoprotein I valine/leucine247 polymorphism and anti-beta2-glycoprotein I antibodies in patients with primary antiphospholipid syndrome | Q73029368 | ||
| G20210A homozygosity in antiphospholipid syndrome secondary to systemic lupus erythematosus | Q73341801 | ||
| HLA class II gene polymorphisms in antiphospholipid syndrome: haplotype analysis in 83 Caucasoid patients | Q73395887 | ||
| Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin | Q73396795 | ||
| The G20210A polymorphism in the 3'-untranslated region of the prothrombin gene in Mexican mestizo patients with primary antiphospholipid syndrome | Q73567845 | ||
| Association of antiphosphatidylserine/prothrombin autoantibodies with HLA class II genes | Q73574482 | ||
| Plasma tumor necrosis factor alpha levels and the -238*A promoter polymorphism in patients with antiphospholipid syndrome | Q73607436 | ||
| The effects of antiphospholipid antibodies obtained from women with SLE/APS and associated pregnancy loss on rat embryos and placental explants in culture | Q73737714 | ||
| Effects of beta2-glycoprotein I and monoclonal anticardiolipin antibodies on extrinsic fibrinolysis | Q73774938 | ||
| Lack of association between thrombosis in primary antiphospholipid syndrome and the recently described thrombophilic 3'-untranslated prothrombin gene polymorphism | Q73962550 | ||
| Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome | Q74151261 | ||
| Dual antibody reactivity to beta2-glycoprotein I and protein S: increased association with thrombotic events in the antiphospholipid syndrome | Q74225454 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 35-52 | |
| P577 | publication date | 2011-03-24 | |
| P1433 | published in | Autoimmunity highlights | Q26853848 |
| P1476 | title | Pathophysiology of the antiphospholipid antibody syndrome | |
| P478 | volume | 2 |
| Q58780730 | Antiphosphatidylserine Antibody as a Cause of Multiple Dural Venous Sinus Thromboses and ST-Elevation Myocardial Infarction |
| Q88984114 | Antiphospholipid syndrome masquerading as a case of infective endocarditis |
| Q91642031 | Antiphospholipid syndrome: a case report with an unusual wide spectrum of clinical manifestations |
| Q54996884 | Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome. |
| Q92239610 | Environmental Triggers of Autoreactive Responses: Induction of Antiphospholipid Antibody Formation |
| Q99552285 | Flare of Antiphospholipid Syndrome in the Course of COVID-19 |
| Q98181529 | Management of anticoagulant-refractory thrombotic antiphospholipid syndrome |
| Q64108214 | New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches |
| Q90432999 | Role of microRNAs in the Development of Cardiovascular Disease in Systemic Autoimmune Disorders |
| Q35308972 | Treatment of the antiphospholipid syndrome |
Search more.